These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36601880)

  • 141. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.
    Li B; Severson E; Pignon JC; Zhao H; Li T; Novak J; Jiang P; Shen H; Aster JC; Rodig S; Signoretti S; Liu JS; Liu XS
    Genome Biol; 2016 Aug; 17(1):174. PubMed ID: 27549193
    [TBL] [Abstract][Full Text] [Related]  

  • 142. Mutation of cancer driver MLL2 results in transcription stress and genome instability.
    Kantidakis T; Saponaro M; Mitter R; Horswell S; Kranz A; Boeing S; Aygün O; Kelly GP; Matthews N; Stewart A; Stewart AF; Svejstrup JQ
    Genes Dev; 2016 Feb; 30(4):408-20. PubMed ID: 26883360
    [TBL] [Abstract][Full Text] [Related]  

  • 143. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.
    Rao RC; Dou Y
    Nat Rev Cancer; 2015 Jun; 15(6):334-46. PubMed ID: 25998713
    [TBL] [Abstract][Full Text] [Related]  

  • 144. Robust enumeration of cell subsets from tissue expression profiles.
    Newman AM; Liu CL; Green MR; Gentles AJ; Feng W; Xu Y; Hoang CD; Diehn M; Alizadeh AA
    Nat Methods; 2015 May; 12(5):453-7. PubMed ID: 25822800
    [TBL] [Abstract][Full Text] [Related]  

  • 145. Molecular and genetic properties of tumors associated with local immune cytolytic activity.
    Rooney MS; Shukla SA; Wu CJ; Getz G; Hacohen N
    Cell; 2015 Jan; 160(1-2):48-61. PubMed ID: 25594174
    [TBL] [Abstract][Full Text] [Related]  

  • 146. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.
    Bosse T; ter Haar NT; Seeber LM; v Diest PJ; Hes FJ; Vasen HF; Nout RA; Creutzberg CL; Morreau H; Smit VT
    Mod Pathol; 2013 Nov; 26(11):1525-35. PubMed ID: 23702729
    [TBL] [Abstract][Full Text] [Related]  

  • 147. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
    Topalian SL; Hodi FS; Brahmer JR; Gettinger SN; Smith DC; McDermott DF; Powderly JD; Carvajal RD; Sosman JA; Atkins MB; Leming PD; Spigel DR; Antonia SJ; Horn L; Drake CG; Pardoll DM; Chen L; Sharfman WH; Anders RA; Taube JM; McMiller TL; Xu H; Korman AJ; Jure-Kunkel M; Agrawal S; McDonald D; Kollia GD; Gupta A; Wigginton JM; Sznol M
    N Engl J Med; 2012 Jun; 366(26):2443-54. PubMed ID: 22658127
    [TBL] [Abstract][Full Text] [Related]  

  • 148. Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer.
    Liu R; Niu Y; Liu C; Zhang X; Zhang J; Shi M; Zou W; Gu B; Zhu H; Wang D; Yuan H; Li W; Zhao D; Zheng Q; Liu R; Chen W; Ma T; Zhang Y
    Cancer Sci; 2023 Apr; 114(4):1229-1239. PubMed ID: 36601880
    [TBL] [Abstract][Full Text] [Related]  

  • 149. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.
    Lefler DS; Snook AE; Bashir B
    Immunotherapy; 2022 Aug; 14(11):885-902. PubMed ID: 35694998
    [TBL] [Abstract][Full Text] [Related]  

  • 150. Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer.
    Du F; Liu Y
    J Clin Lab Anal; 2022 Jan; 36(1):e24141. PubMed ID: 34817097
    [TBL] [Abstract][Full Text] [Related]  

  • 151. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
    Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
    AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
    [TBL] [Abstract][Full Text] [Related]  

  • 152. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 153. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
    Tan E; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
    [No Abstract]   [Full Text] [Related]  

  • 154. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer.
    Chen Y; Liu C; Zhu S; Liang X; Zhang Q; Luo X; Yuan L; Song L
    Int Immunopharmacol; 2021 Jul; 96():107607. PubMed ID: 33831809
    [TBL] [Abstract][Full Text] [Related]  

  • 155. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
    Krieger T; Pearson I; Bell J; Doherty J; Robbins P
    Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
    [TBL] [Abstract][Full Text] [Related]  

  • 156. Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors.
    Chen JA; Ma W; Yuan J; Li T
    Cancer Treat Res; 2020; 180():251-279. PubMed ID: 32215873
    [TBL] [Abstract][Full Text] [Related]  

  • 157. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
    Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
    Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
    [TBL] [Abstract][Full Text] [Related]  

  • 158. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 159. Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors.
    Lengyel CG
    Curr Drug Targets; 2021; 22(9):968-976. PubMed ID: 33970843
    [TBL] [Abstract][Full Text] [Related]  

  • 160. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
    Uruga H; Mino-Kenudson M
    Virchows Arch; 2021 Jan; 478(1):31-44. PubMed ID: 33486574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.